Osimertinib 80 mg is an oral targeted anticancer medicine containing 80 mg of osimertinib.
Product identity
| Characteristic | Information |
|---|---|
| Generic name | Osimertinib |
| Strength | 80 mg |
| Dosage form | Tablet |
| Route | Oral |
| Drug class | EGFR tyrosine kinase inhibitor |
| Main disease area | EGFR-mutated NSCLC |
| Reference brand | Tagrisso |
| Reference company | AstraZeneca |
| Examples of generic brands | Tagrix, Osicent, Osimert |
Therapeutic role
Osimertinib is used in selected EGFR-mutated NSCLC settings, including adjuvant therapy after resection, treatment following chemoradiation in unresectable stage III disease, first-line advanced disease and selected previously treated T790M-positive disease.
Mechanism
Osimertinib irreversibly inhibits selected mutant EGFR forms, including exon 19 deletion, L858R and T790M.
Reference product
Tagrisso is the established reference brand. Generic products containing osimertinib should not be described as Tagrisso without evidence.
Safety
Important safety concerns include interstitial lung disease/pneumonitis, QTc prolongation, cardiomyopathy, keratitis and aplastic anemia.
Verification
Product identity should be checked against packaging and reliable manufacturer or regulatory documentation.